Navigation Links
Medizone International, Inc. (MZEI.PK) Announces it has Established its Own BSL2A Certified Laboratory Located in Innovation Park, Queen's University at Kingston, Ontario, Canada.
Date:7/7/2009

SAN FRANCISCO, July 7 /PRNewswire-FirstCall/ -- "This is a fully equipped bio-safety level 2 laboratory dedicated exclusively to Medizone research," stated Dr. Michael Shannon Director of Medical Affairs for Medizone. "This new laboratory is located in the heart of one of the finest bio-medical communities in the country and will provide a primary research and development platform for the Corporation as it proceeds down what is now a clear path to commercialization with its lead product, AsepticSure(TM). Given the outstanding range of bactericidal kill rates we have achieved to date ( 4.4 log /99.994% to 5 log /99.999%) with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand our scientific horizons through collaborative arrangements in many diverse and exciting new applications. The current pandemic of H1 N1 influenza occurring world-wide reminds us how vulnerable we are to new infectious diseases and why new advanced and innovative technologies that combat such infectious agents are seriously needed. The Medizone AsepticSure(TM) system is just such an innovation in the battle against infections which claim countless lives every day world-wide. The Company now has a platform to continue an expanded laboratory research program even as it prepares for the commencement of hospital beta testing of its hospital sterilization system later this summer."

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. If current trials continue to proceed successfully they will be followed by a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are targeted to commence in the 4 quarter of this year.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The company disclaims any obligation or intention to update any forward-looking statement.

         Investor Relations: 800-953-3350 / web site: www.medizoneint.com
                       E-mail: operations @ medizoneint.com


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc.
2. The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
3. Medizone Announces a Second Round of Trials Have Begun.
4. Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts
5. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
6. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
7. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
8. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
9. TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock
10. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
11. DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: